July 14, 2014
1 min read

Matrix metalloproteinase-9 test enables reliable dry eye diagnosis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A matrix metalloproteinase-9 test showed high positive and negative agreement in confirming dry eye disease diagnoses, according to a study.

The prospective, masked, multicenter study compared the InflammaDry test (Rapid Pathogen Screening) with other clinical testing methods such as tear breakup time, Schirmer testing and corneal staining. All testing was performed with and without the Ocular Surface Disease Index being used to confirm the presence of dry eye disease.

Investigators enrolled 237 patients, of which 146 patients were assigned to the dry eye group, and 91 patients comprised a control group. All patients underwent conventional dry eye screening in addition to screening with InflammaDry.

The InflammaDry test had a total positive agreement of 81% and a negative agreement of 98% when OSDI scores were included in the analysis. Positive agreement was 86% and negative agreement was 97% when OSDI scores were excluded from the analysis.

Disclosure: The design of the study and collection of data were sponsored by Rapid Pathogen Screening (RPS). No sponsorship was received for the analysis and interpretation of study data. Sambursky has an affiliation with RPS but was not an investigator. The remaining authors have no relevant financial disclosures.